Who
Kim R. Tsuchimoto
Director
Company insider
Files Form 4 as: Chief Financial Officer, Monopar Therapeutics; Chief Financial Officer, Raptor Pharmaceutical; CFO, Treasurer & Sect'y, Raptor Pharmaceuticals.
In numbers
- Trades disclosed
- 132
- Buys
- 1
- Sells
- 8
- Bought
- $2,600
- Sold
- $2.3M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 26 May 2006
- Last trade
- 26 Aug 2026
- Last filed
- 28 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | $62K2,055 at $30.00 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,035 at $0.00 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | $28K2,035 at $14.00 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $53K485 at $108.83 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,055 at $0.00 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,035 at $0.00 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $67K615 at $109.56 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $77K700 at $110.65 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $123K1,098 at $111.84 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $68K602 at $112.93 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $67K590 at $113.84 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,055 at $0.00 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | $62K2,055 at $30.00 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | $28K2,035 at $14.00 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $53K485 at $108.83 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $67K615 at $109.56 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $77K700 at $110.65 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $123K1,098 at $111.84 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $68K602 at $112.93 | filing |
| 26 Aug 2026filed 28 Aug 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Sold | $67K590 at $113.84 | filing |
News
No headline names them, or the companies they trade most, lately.